The Scottish Medicines Consortium (SMC) has completed its initial assessment of the evidence for the above product using the ultra-orphan framework.
Indication under review: Treatment of activated phosphoinositide 3-kinase delta (PI3K-delta) syndrome (APDS) in adult and paediatric patients 12 years of age and older.
________________________________________________________________________________________________________________________________________
From 08 December 2025 leniolisib (Joenja®) can be prescribed within the ultra-orphan pathway while further evidence on its effectiveness is generated. At the end of the data collection period, the company will provide an updated submission for reassessment to allow a decision on its routine use in NHSScotland.
Medicine details
- Medicine name:
- leniolisib (Joenja)
- SMC ID:
- SMC2836
- Indication:
Treatment of activated phosphoinositide 3-kinase delta (P13Kδ) syndrome (APDS) in adult and paediatric patients 12 years of age and older.
- Pharmaceutical company
- Pharming Group NV
- BNF chapter
- Nutrition and blood
- Submission type
- Ultra-orphan initial assessment
- Date advice published
- 08 December 2025